Posted on July 17th, 2014
Mr. Commissiong was appointed President and CEO of Amarantus BioScience in October 2011.
Amarantus BioScience Holdings, Inc. is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine (“Eltoprazine”), a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”).
We have just completed what was an extremely successful Alzheimer’s Association International Conference in Copenhagen...Read More »
Posted on July 9th, 2014
Over the last 24 hours I have received several emails and inquiries from investors as it relates to understanding exactl...Read More »
Posted on July 8th, 2014
On July 1st, approximately 14,456 shares of the Company’s common stock were purchased by employees of the Company un...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
We are an exclusive, online media publication where public and privatively held firms alike share insights about their companies and industries...Learn More »